|Bid||15.15 x 900|
|Ask||15.84 x 800|
|Day's Range||15.18 - 15.94|
|52 Week Range||11.80 - 53.75|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.10|
The leading exchange-traded funds that track the industry are down precipitously this spring as a number of companies have reported bad news.
NEW YORK, NY / ACCESSWIRE / April 20, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ:IMVT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive (the "Class Period").
LOS ANGELES, CA / ACCESSWIRE / April 20, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ:IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.